Jennifer Tousignant

Jennifer Tousignant serves as the Chief Legal Officer with a distinguished career in the biotechnology sector, where she has developed expertise across various technologies including small molecules, biologics, cell, and gene therapies. Her work spans multiple therapeutic areas such as rare disease, immune-mediated disease, neurodegenerative disease, and oncology. Previously, Tousignant was the Senior Vice President of Legal at Sana Biotechnology, Inc., where she led a comprehensive legal team supporting strategic transactions, business development, intellectual property, litigation, and more. She played a significant role in corporate governance and financing activities at Sana. Prior to this, she headed the Legal department at Xilio Therapeutics, overseeing all legal and compliance issues, and served as Chief IP Counsel at TESARO, Inc., where she established and led the intellectual property function. Tousignant was instrumental in TESARO’s transactional work and its acquisition by GSK. Her earlier tenure at Genzyme Corporation (now part of Sanofi) saw her in roles escalating from research to leading a legal team with global IP responsibilities. She was integral to the global launch teams for several products and supported business development for the rare disease and multiple sclerosis units at Genzyme. Tousignant earned her JD, magna cum laude, from Suffolk University School of Law and holds a BA in Chemistry with Honors from the University of Virginia.